[ad_1]
September 2, 2020
The Swiss pharmaceutical giant Roche has announced that it will soon launch a rapid test for the diagnosis of Covid-19, capable of providing results in 15 minutes. In Europe it should be available By the end of September and the Swiss pharmaceutical group intends to ask for a green light also in the United States.
This is a test that can be performed without a laboratory infrastructure, through a nasal swaband has a high degree of reliabilityinforms the Basel company in a note. The rapid test has a sensitivity of 96.52 percent and a specificity of 99.68 percent, the efficacy was determined by analyzing 426 samples by “two independent study centers.”
According to Roche, the test will be available By the end of September for all markets that accept the CE mark, while an application will soon be submitted to the U.S. Food and Drug Administration (FDA), the federal body that regulates experimental drugs, foods, and therapies , for the authorization of emergency use.
The Rhine giant plans to put on the market initially 40 million tests per month, but by the end of the year the production capacity will more than double.
“As flu season approaches, it is important to know if a person has the flu or coronavirus,” says Thomas Schinecker, director of Roche’s Diagnostics Division.
The news was received very positively by analysts: the test will allow quick checks at the entrance of sanitary facilitieswrites a Vontobel expert; A Mirabaud Securities specialist also predicts a very high demand for the new product, especially in regions still heavily affected by the SARS-CoV-2 pandemic.
[ad_2]
